Target intelligence / Profile preview

Ras GTPase-activating protein 4 (RASA4)

Target
RASA4
Molecular classification
Enzyme (GTPase-activating protein, GAP), Member of GAP1 family, C2 domain containing protein
01

Overview

Ras GTPase-activating protein 4 (RASA4) is an enzyme encoded by the RASA4 gene and belongs to the GAP1 family of GTPase-activating proteins. RASA4 operates as a calcium-dependent suppressor of the Ras/mitogen-activated protein kinase pathway. In response to elevated intracellular calcium, RASA4 translocates to the plasma membrane, where it promotes the intrinsic GTPase activity of Ras, converting it from its active GTP-bound form to its inactive GDP-bound state. This action prevents Ras from propagating signals that regulate gene expression, cell growth, and cell differentiation. RASA4 participates in multiple biological processes, including calcium signaling, immune cell function, and negative regulation of pathological airway remodeling. Multiple isoforms exist due to transcript variants. While RASA4 is considered a relevant therapeutic target due to its regulatory role in oncogenic and pathological pathways, no drugs directly modulating RASA4 are in clinical use.

Other names
CAPRIGAPLCalcium-promoted Ras inactivatorRas p21 protein activator 4RasGAP-activating-like protein 2Ca²⁺-promoted Ras inactivatorKIAA0538
02

Mechanism of action

Drugs that inhibit or modulate the Ras pathway may exert effects by altering RASA4-mediated Ras inactivation, but no direct pharmacological modulators are described for RASA4 itself

03

Biological functions

Signal transductionRegulation of Ras/mitogen-activated protein kinase pathwaySuppression of Ras activityRegulation of gene expressionCell growthCell differentiationCalcium sensing and transduction
04

Disease associations

Cancer (regulation of Ras pathway relevant to oncogenesis)Pathological airway remodelingImmune system regulation (threshold setting in dendritic cells)Other (potential roles in cardiovascular and neurological systems based on expression profiles)
05

Safety considerations

As RASA4 is involved in suppression of Ras-mediated signaling, therapeutic modulation may risk dysregulation of cell growth, immune responses, or contribute to unintended oncogenesis or immune dysfunction; however, explicit safety data for directed RASA4 modulation are lacking
06

Interacting drugs

No specific drugs directly targeting RASA4 are currently described in major databases or literature; Ras pathway inhibitors may indirectly affect its functional axis
07

Biomarkers

No established clinical biomarkers specific for RASA4 patient selection or drug efficacy monitoring

Beyond the preview

Go deeper on Ras GTPase-activating protein 4 (RASA4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ras GTPase-activating protein 4 (RASA4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call